-
Mashup Score: 1A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma - 1 year(s) ago
Single-agent monoclonal antibody therapy against programmed death-ligand 1 (PD-L1) has modest effects in malignant pleural mesothelioma. Radiation therapy can enhance the antitumor effects of immunotherapy. Nevertheless, the safety of combining anti-PD-L1 therapy with stereotactic body radiation therapy (SBRT) is unknown. We present the results of a phase 1 trial to evaluate the safety of the…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR exon 20 insertion mutations - 1 year(s) ago
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for 5-10% of EGFR-mutated non-small cell lung cancer. CLN-081 (formerly known as TAS6417), a novel covalent EGFR-tyrosine kinase inhibitor (TKI), exhibits pan-mutation selective efficacy, including exon 20 insertions, in the clinical setting. However, some patients may not respond to CLN-081 and resistance to CLN-081 may…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Preclinical work #JTOCRR suggests the EGFR C797S mutation confers resistance to #EGFR TKI CLN-081 (being explored in #EGFRex20). The small molecule pimitespib, a selective heat shock protein 90 inhibitor, may help overcome resistance. @JTOonline https://t.co/Rm2nDqofM0
-
-
Mashup Score: 1The EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR exon 20 insertion mutations - 1 year(s) ago
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for 5-10% of EGFR-mutated non-small cell lung cancer. CLN-081 (formerly known as TAS6417), a novel covalent EGFR-tyrosine kinase inhibitor (TKI), exhibits pan-mutation selective efficacy, including exon 20 insertions, in the clinical setting. However, some patients may not respond to CLN-081 and resistance to CLN-081 may…
Categories: Latest HeadlinesTweet-
Preclinical work #JTOCRR suggests the EGFR C797S mutation confers resistance to #EGFR TKI CLN-081 (being explored in #EGFRex20). The small molecule pimitespib, a selective heat shock protein 90 inhibitor, may help overcome resistance. @JTOonline https://t.co/Rm2nDqoNBy
-
-
Mashup Score: 7ALK-positive adenocarcinoma after acquired resistance to lorlatinib and transformation to small-cell lung cancer: a case report - 1 year(s) ago
Small cell lung cancer (SCLC) transformation is a phenomenon that is rarely described in anaplastic lymphoma kinase (ALK)-rearranged cancers after treatment with ALK-tyrosine kinase inhibitors (TKIs); however, it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Case report in #JTOCRR of #ALK NSCLC with #SCLC transformation as mechanism of resistance to lorlatinib. Will be important to watch patterns of late acquired resistance to our current agents and to consider biopsy when feasible. @JTOonline https://t.co/M5FeyCJIyI
-
-
Mashup Score: 8
BRAF mutations (present in 2-3% of non-small cell lung cancer) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (ICI)-based systemic therapies, yet this is required for appropriate treatment decisions which…
Categories: Hem/Oncs, Latest HeadlinesTweet-
BRAF-mt nsclc: To treat with ICI-regimens or BRAF/MEKi first? - 53pts real-world dataset (V600E=35; NonV600E=18) - ORR 38-43% from ICI-based tx - ORR 33% from BRAF/MEKi Further data to suggest these are both reasonable options @OncoAlert #LCSM https://t.co/gmiLEzBhgL
-
-
Mashup Score: 1
BRAF mutations (present in 2-3% of non-small cell lung cancer) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (ICI)-based systemic therapies, yet this is required for appropriate treatment decisions which…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Real-world analysis of 53 pts with #BRAF NSCLC #JTOCRR. 1L TKI RR 33% and mPFS 15.2m while 1L IO RR 38-43% and mPFS 10.5-10.8m. Optimal 1L treatment not yet clear for NSCLC. Will PDL1, TMB, co-mutation, smoking status help guide future efforts? @JTOonline https://t.co/ubPI0ZYdHC
-
-
Mashup Score: 7Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study - 1 year(s) ago
Epidermal growth factor receptor (EGFR) mutations drive a subset of non-small cell lung cancer (NSCLC). Patients harboring the common EGFR mutations, deletion of exon 19 (Ex19del) and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. However, the effect of osimertinib on NSCLC with atypical EGFR mutations is not well described. This multicenter retrospective study…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Retrospective analysis of osimertinib in 50 pts with atypical #EGFR NSCLC in #JTOCRR. Median time to d/c 17.2m for L861Q, 7.8m for G719X, 1.5m for exon 20 insertion. Afatinib is the approved standard for atypical; amivantamab and mobocertinib for ex20ins. https://t.co/kQiqpEJYTZ
-
-
Mashup Score: 0Building on a Legacy - 1 year(s) ago
Sixteen years ago, in 2006, founding editor Prof. James Jett and the International Association for the Study of Lung Cancer (IASLC) launched the Journal of Thoracic Oncology (JTO).1 The JTO aimed to provide the IASLC with new opportunities and expand horizons. In 2013, Prof. Jett handed over the editorship to Prof. Alex Adjei. By this time, the JTO was an established, international journal…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
All of us at @IASLC are excited to welcome Dr. Emily Stone as the new Editor in Chief of JTO CRR! Learn about her background and motivation for joining the #JTOCRR Editorial Team in this editorial. https://t.co/A3z9pyxlci #LCSM https://t.co/YykuWZaGjg
-
-
Mashup Score: 0Building on a Legacy - 1 year(s) ago
Sixteen years ago, in 2006, founding editor Prof. James Jett and the International Association for the Study of Lung Cancer (IASLC) launched the Journal of Thoracic Oncology (JTO).1 The JTO aimed to provide the IASLC with new opportunities and expand horizons. In 2013, Prof. Jett handed over the editorship to Prof. Alex Adjei. By this time, the JTO was an established, international journal…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations to Dr. Emily Stone, deputy chair of @TOGAANZ and the new editor of JTO Clinical and Research Reports. See the new editorial "Building on a Legacy" in #JTOCRR @JTOonline https://t.co/f6ADVImSJY
-
-
Mashup Score: 4Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report - 1 year(s) ago
Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable identified risk…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report https://t.co/oN7CTlDkKH #lcsm @JTOonline
-
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma https://t.co/Bz3pqgTg9c #lcsm #mesothelioma